UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
Objectives In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term mi...
Saved in:
Main Authors: | Jacqueline Palace, Martin Duddy, Thomas Bregenzer, Mike Boggild, Joel Oger, Helen Tremlett, Charles Dobson, Fheng Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2014-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/4/1/e004073.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alexithymia in multiple sclerosis: past, present and future
by: Samar S. Ayache, et al.
Published: (2025-02-01) -
A shadow Markov equation
by: Bonin, Nathan, et al.
Published: (2023-11-01) -
The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis
by: Nupur Greene, et al.
Published: (2022-10-01) -
Fitting Markov property to genetic sequences
by: Jurgita Židanavičiūtė, et al.
Published: (2023-09-01) -
Shared prognostic information in amyotrophic lateral sclerosis – systematic assessment of the patients’ perception of neurofilament light chain and the ALS functional rating scale
by: Lukas Maximilian Möhwald, et al.
Published: (2025-02-01)